A Phase 2 interventional study of MY008211A tablets in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by Wuhan Createrna Science and Technology Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.
The purpose of this study is to determine whether MY008211A is efficacious and safe for the treatment of PNH patients who are naïve to complement inhibitor therapy, including anti-C5 antibody.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
This study's planned enrollment of 40 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Browse Hemoglobinuria, Paroxysmal studies →Wuhan Createrna Science and Technology Co., Ltd is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MY008211A at a dose of 400 mg orally b.i.d
Drug: MY008211A tablets
Participants will receive MY008211A at a dose of 600 mg orally b.i.d
Drug: MY008211A tablets
dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
Also known as: MY008211A
The proportion of subjects with an increase in hemoglobin concentration ≥ 20 g/L from baseline among subjects who do not receive RBC transfusion after 4 weeks of dosing
Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥ 20 g/L assessed , in the absence of red blood cell transfusions
Time frame: Day 70
The proportion of patients with an increase in hemoglobin ≥ 20 g/L from baseline among those without RBC transfusion
The proportion of patients with an increase in hemoglobin ≥ 20 g/L from baseline among those without RBC transfusion
Time frame: Day14, 21, 28, 42, 56
The proportion of patients with hemoglobin ≥ 120 g/L among those without RBC transfusion
The proportion of patients with hemoglobin ≥ 120 g/L among those without RBC transfusion
Time frame: Day14, 21, 28, 42, 56 and 70
Change in hemoglobin concentration from baseline in patients without RBC transfusion
Change in hemoglobin concentration from baseline in patients without RBC transfusion
Time frame: Day14, 21, 28, 42, 56 and 70
Change in LDH level from baseline
Change in LDH level from baseline
Time frame: Day7, 14, 21, 28, 42, 56 and 70
The proportion of patients with hemolysis controlled
The proportion of patients with hemolysis controlled (defined as LDH \< 1.5 ULN)
Time frame: Day7, 14, 21, 28, 42, 56 and 70
Change in reticulocyte count from baseline in patients without RBC transfusion
Change in reticulocyte count from baseline in patients without RBC transfusion
Time frame: Day7, 14, 21, 28, 42, 56 and 70
Change in indirect bilirubin level from baseline
Change in indirect bilirubin level from baseline
Time frame: Day7, 14, 21, 28, 42, 56 and 70
The proportion of patients without RBC transfusion
The proportion of patients without RBC transfusion
Time frame: Day14, 21, 28, 42, 56 and 70
Change in the average weekly amount of RBC transfused during the efficacy observation period
Change in the average weekly amount of RBC transfused during the efficacy observation period compared with that pre-dose
Time frame: Day70
Change From Baseline in FACIT-Fatigue Questionnaire
Change from baseline in FACIT-Fatigue scores. The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.
Time frame: Day7, 14, 21, 28, 42, 56 and 70
Changes from baseline in alternative complement pathway activity
Alternative complement pathway activity measured by the WIESLAB® kit.
Time frame: Day14, 28, 56 and 70
Change in the amount of fragment Bb of CFB in plasma from baseline
Bb fragment cleaved by factor B of complement.
Time frame: Day14, 28, 56 and 70
Change in the level of PNH RBC clones from baseline in patients without RBC transfusion.
Change from baseline in the level of PNH red cell clones.
Time frame: Day70
Incidence of Adverse Events (AEs) between Day 1 and Day 70
Adverse Events (AEs)
Time frame: Day 70
No study locations are listed for this record.
Start is estimated for Dec 2025; primary completion for Jul 2027, 19 months later.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 19 months is above that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lanoracopan
Wuhan Createrna Science and Technology Co., Ltd